Markforged devises reverse merger plan
Microsoft, Porsche and Siemens have all scored another win as Markforged pursues a reverse merger that will net it $425m in gross proceeds.
Berkshire Grey picks reverse merger route
SoftBank’s robotics portfolio company Berkshire Grey has lined up a reverse merger with Revolution Acceleration Acquisition Corp and will be valued at $2.7bn.
ReNew Power charges towards Nasdaq
Having abandoned plans for an IPO three years ago, ReNew Power has now settled on a reverse merger and will secure proceeds worth $1.2bn.
Joby Aviation takes flight for reverse merger
The Intel Capital, JetBlue Technology Ventures, Toyota AI Ventures and Uber-backed flying car developer is set to list on the NYSE.
WingArc1st to fly to public markets
The business software producer is set to float in a $172m offering on TSE that will enable Data Applications, Itochu, Pksha, Sansan, Suzuyo, SystemExe, Teikoku DataBank and Toshiba Digital Solutions to exit.
Humacyte hooks into Alpha Healthcare
Fresenius Medical Care and Access Industries-backed Humacyte will merge with Alpha Healthcare Acquisition Corp to become a public business with a market cap of $1.1bn.
AEye identifies reverse merger opportunity
Aisin, Airbus, Intel, LG, SBI, Hella and SK Hynix all celebrated a win as AEye agreed to a reverse merger with CF Finance to list on Nasdaq at a $2bn valuation.
Cloopen completes $320m IPO
Cloopen, also known as Ronglian and Yuntongxun, priced its shares at $16 to raise $320m in an initial public offering that provided an exit for Telstra Ventures and New Oriental.

Other News

Adagene advances to IPO
WuXi AppTec and New World Development-backed Adagene has raised close to $140m in its initial public offering after having secured $155m in equity financing.
Owlet grows into public company
Amazon-backed Owlet Baby Care has agreed to a reverse merger with special purpose acquisition company Sandbridge for a post-deal valuation of $1.39bn.
Decibel resonates with public markets
The hearing loss treatment developer has raised more than $127m in its initial public offering that offered exits to Alphabet, GlaxoSmithKline and Regeneron.
Coupang books $1bn IPO ticket
Coupang is reportedly looking to achieve a $50bn market cap following a planned listing that would offer an exit to both SoftBank and its Vision Fund.
NexImmune collects IPO proceeds
NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.
Vor Biopharma forces through $177m IPO
The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

Editor's Picks

Sana Bio plants itself on public markets
The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.
Wish comes true in $1.1bn IPO
The mobile commerce platform developer priced its initial public offering at the top of its range, with JD.com set to exit in the flotation.
Airbnb aces IPO to raise $3.49bn
The Alphabet-backed accommodation marketplace priced its initial public offering well above its range in the second huge flotation this week, to secure a $47bn valuation.
DoorDash lets in $3.37bn through IPO
SoftBank Vision Fund is the largest investor in the food delivery service, which has priced an upsized initial public offering roughly doubling its valuation six months ago.
test reg